The United States Supreme Court will review a patent dispute between HIKMA PHARMACEUTICALS PLC and Amarin over the cardiovascular drug Vascepa. The case centers on "skinny labels," which allow generic manufacturers to omit patented uses of branded medications. A ruling could reshape generic competition for drugs like Vascepa, which generated $228.6 million for Amarin in 2024.
US Supreme Court to hear Amarin patent dispute with Hikma
The U.S. Supreme Court will hear a patent dispute between Amarin and Hikma regarding generic drug labels. The ruling could impact competition across the sector.
Xurve View
洞察:
Xurve View











